DRMA Files 8-K on Shareholder Vote Submission
Ticker: DRMAW · Form: 8-K · Filed: Jan 12, 2024 · CIK: 1853816
| Field | Detail |
|---|---|
| Company | Dermata Therapeutics, Inc. (DRMAW) |
| Form Type | 8-K |
| Filed Date | Jan 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, 8-K
TL;DR
**DRMA just filed an 8-K about submitting matters to a shareholder vote.**
AI Summary
Dermata Therapeutics, Inc. (DRMA) filed an 8-K on January 12, 2024, to report that it submitted matters to a vote of its security holders. This filing indicates that the company is engaging its shareholders on important decisions, which is a standard corporate governance practice. For investors, this means the company is moving forward with strategic initiatives that require shareholder approval, potentially impacting future operations or capital structure.
Why It Matters
This filing signals that Dermata Therapeutics is progressing with corporate actions requiring shareholder input, which could influence the company's strategic direction and financial health.
Risk Assessment
Risk Level: low — This filing is a procedural update about submitting matters for a shareholder vote and does not inherently introduce new financial or operational risks.
Analyst Insight
A smart investor would monitor subsequent filings (like proxy statements) to understand the specific matters being put to a vote and assess their potential impact on the company's future and stock value.
Key Numbers
- $0.0001 — par value per share (This is the nominal value of each share of Common Stock.)
Key Players & Entities
- Dermata Therapeutics, Inc. (company) — registrant
- DRMA (company) — trading symbol for Common Stock
- DRMAW (company) — trading symbol for Warrants
- Nasdaq Capital Market (company) — exchange where securities are registered
- $0.0001 (dollar_amount) — par value per share of Common Stock
FAQ
What was the specific event reported in this 8-K filing by Dermata Therapeutics, Inc.?
The specific event reported was the 'Submission of Matters to a Vote of Security Holders' as of January 12, 2024.
What is the trading symbol for Dermata Therapeutics, Inc.'s Common Stock and on which exchange is it registered?
The trading symbol for Dermata Therapeutics, Inc.'s Common Stock is DRMA, and it is registered on The Nasdaq Capital Market.
Does Dermata Therapeutics, Inc. also have warrants registered, and if so, what is their trading symbol and exchange?
Yes, Dermata Therapeutics, Inc. also has Warrants, exercisable for one share of Common Stock, with the trading symbol DRMAW, also registered on The Nasdaq Capital Market.
What is the par value per share of Dermata Therapeutics, Inc.'s Common Stock?
The par value per share of Dermata Therapeutics, Inc.'s Common Stock is $0.0001.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 12, 2024.
Filing Stats: 725 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-01-12 16:06:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share DRMA The Nasdaq Capital M
Filing Documents
- drma_8k.htm (8-K) — 39KB
- 0001654954-24-000520.txt ( ) — 179KB
- drma-20240112.xsd (EX-101.SCH) — 6KB
- drma-20240112_lab.xml (EX-101.LAB) — 16KB
- drma-20240112_cal.xml (EX-101.CAL) — 1KB
- drma-20240112_pre.xml (EX-101.PRE) — 12KB
- drma-20240112_def.xml (EX-101.DEF) — 4KB
- drma_8k_htm.xml (XML) — 5KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On January 12, 2024, Dermata Therapeutics, Inc. (the " Company ") held a special meeting of stockholders (the " Special Meeting "). The matters voted on at the Special Meeting were: (1) the authorization, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of the Company's Common Stock underlying certain warrants issued by the Company pursuant to that certain Inducement Letter, dated as of November 16, 2023, by and between the Company and the investor named on the signatory page thereto, and the Engagement Letter between the Company and H.C. Wainwright & Co., LLC, dated as of September 30, 2023, in an amount equal to or in excess of 20% of the Company's Common Stock outstanding immediately prior the issuance of such warrants (the " Issuance Proposal "); (2) the ratification of the appointment of Moss Adams LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 (the " Auditor Proposal "); and (3) the approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the foregoing proposals (the " Adjournment Proposal "). At the Special Meeting, all of the matters voted on were approved, based upon an aggregate of 3,189,034 shares of Common Stock outstanding as of November 17, 2023, which was the record date for the Special Meeting. The final voting results were as follows: Proposal No. 1 : The Issuance Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 789,001 5,008 231 485,871 Proposal No. 2 : The Auditor Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 1,269,895 9,551 665 0
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. DERMATA THERAPEUTICS, INC . Date: January 12, 2024 By: /s/ Gerald T. Proehl Gerald T. Proehl Chief Executive Officer 3